AI assistant
KALA BIO, Inc. — Director's Dealing 2017
Jul 19, 2017
35091_dirs_2017-07-19_8ee33b4b-8e97-4a0c-b6c4-bf7ecc963af9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2017-07-19
Reporting Person: Chen Hongming (Chief Scientific Officer, 10% Owner)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 46080 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $2.24 | 2023-09-27 | Common Stock (5769) | Direct | |
| Stock Option (right to buy) | $2.30 | 2024-10-02 | Common Stock (110236) | Direct | |
| Stock Option (right to buy) | $5.21 | 2025-10-02 | Common Stock (21431) | Direct | |
| Stock Option (right to buy) | $3.34 | 2026-06-17 | Common Stock (154635) | Direct |
Footnotes
F1: This option was granted on September 27, 2013 and vests over four years, with 25% of the shares underlying the option vested on September 27, 2014 and an additional 2.0833% of the shares vesting at the end of each successive one-month period thereafter.
F2: This option was granted on October 2, 2014 and vests over four years, with 2.0833% of the shares underlying the option vested on August 21, 2014 and an additional 2.0833% of the shares vesting at the end of each successive one-month period thereafter.
F3: This option was granted on October 2, 2015 and vests over four years, with 25% of the shares underlying the option vested on October 2, 2016 and an additional 2.0833% vesting at the end of each successive one-month period thereafter.
F4: This option was granted on June 17, 2016 and vests over four years, with 25% of the shares underlying the option vesting on June 17, 2017 and an additional 2.0833% vesting at the end of each successive one-month period thereafter.